Axsome Therapeutics (AXSM) Gross Profit (2022 - 2026)

Axsome Therapeutics has reported Gross Profit for 5 years, with the latest figure at $176.5 million in Q1 2026.

• Quarterly Gross Profit rose 58.03% year-over-year to $176.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $655.8 million (up 136.68% YoY) and the FY2025 annual result came in at $591.0 million, up 67.72% from the prior year.
• Gross Profit slipped to $176.5 million in Q1 2026 per AXSM's latest filing, from $183.7 million in the prior quarter.
• Over five years, Gross Profit peaked at $183.7 million in Q4 2025 and troughed at -$10.0 million in Q4 2024.
• A 5-year average of $80.7 million and a median of $73.9 million in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2024 and 2025: Gross Profit sank 115.61% in 2024, then jumped 1934.13% in 2025.
• Over 5 years, Gross Profit stood at $22.1 million in 2022, then jumped by 190.54% to $64.2 million in 2023, then tumbled by 115.61% to -$10.0 million in 2024, then surged by 1934.13% to $183.7 million in 2025, then dropped by 3.92% to $176.5 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $176.5 million, $183.7 million, and $159.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.